Welcome to MIORG, an innovative immuno-oncology research group at the University of Turku and part of the InFLAMES Flagship. Our mission is to revolutionize cancer treatment by harnessing the power of the immune system through cutting-edge academic research and translational innovation. Our ultimate goal is to help patients overcome resistance to immunotherapies, leading to better treatment responses and improved quality of life.
At the heart of our research strategy is a reverse translational approach. We begin with patient biopsies to uncover new biomarkers of resistance to immunotherapies. These biomarkers can serve as prognostic tools and as targets for novel adjuvant immunotherapies. We then validate their functions in well-established in vivo and ex vivo models, setting the stage for the development of new therapeutic concepts. Ultimately, our aim is to combine these innovations with current immunotherapies, offering renewed hope to patients who previously had limited treatment options.
Our vision is to conduct world-class research that unlocks the full potential of immune checkpoint therapies and cancer vaccines, particularly for patients with refractory conditions. Using metastatic melanoma as our primary model, we aspire to make a lasting impact in the field of immuno-oncology.
To achieve this, we employ state-of-the-art technologies such as Mass Cytometry and Digital Spatial Profiling (NanoString) to analyze solid and liquid biopsies together with clinical data, providing deep insight into cancer–immune interactions.
As part of the University of Turku’s innovation ecosystem, and in close collaboration with the InFLAMES Flagship, MIORG is committed to bridging fundamental discoveries with translational innovation. Our programs contribute directly to the university’s mission of advancing science and supporting the development of future therapies and diagnostics for patients in need.
Carlos Rogerio Figueiredo, PhD – Founder